OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Coupe on the Background of IMM60 With Pembrolizumab in Melanoma or NSCLC

August 30th 2023

Nicholas Coupe, MBBS, PhD, discusses the rationale for investigating IMM60 with pembrolizumab in patients with advanced melanoma or metastatic non-small cell lung cancer, as well as key background information that led to this investigation.

Dr Santin on the Investigation of Sacituzumab Govitecan in Endometrial Cancer

August 30th 2023

Alessandro Santin, MD, discusses the investigation of sacituzumab govitecan in patients with recurrent endometrial carcinoma overexpressing TROP2.

Dr Barzi on the Evolution of Treating Gastroesophageal Cancers

August 30th 2023

Afsaneh Barzi, MD, PhD, discusses challenges treating oncologists face when aiming to navigate the treatment landscape of patients with gastroesophageal cancers and highlights the evolution of treatments for patients with these diseases.

Dr Cannon on Improving Responses With Immunotherapy in Ovarian Cancer

August 30th 2023

Martin Cannon, PhD, discusses explanations for the lack of success with immune checkpoint inhibitors in ovarian cancer, and how to potentially improve responses to immunotherapy approaches in this tumor type.

Dr Kambhampati on the Rationale For Evaluating Real-World Outcomes With Brexu-Cel in MCL

August 30th 2023

Swetha Kambhampati, MD, discusses the rationale for evaluating outcomes with in a subgroup anlaysis of patients with relapsed/refractory mantle cell lymphoma, and how prior data from the phase 3 ZUMA-2 study supported the inception of this trial.

Dr Le on the Investigation of Osimertinib and Chemotherapy in Metastatic Lung Cancer

August 29th 2023

Xiuning Le, MD, PhD, discusses ongoing and future investigations with osimertinib and chemotherapy in patients with metastatic lung cancer.

Dr Fonkoua on Clinical Trial Enrollment Disparities in Liver Cancer

August 29th 2023

Lionel A. Kankeu Fonkoua, MD, discusses prevalent liver cancer clinical trial enrollment disparities.

Dr Kambhampati on the Potential Use of Brexu-Cel in Earlier Treatment Lines in MCL

August 29th 2023

Swetha Kambhampati, MD, discusses how findings from a subgroup analysis of investigating the use of brexucabtagene autoleucel in relapsed/refractory mantle cell lymphoma may support the continued exploration of this agent in earlier lines of therapy.

Dr Monga on the Background of Investigating PRT811 in Glioma and Melanoma

August 29th 2023

Varun Monga, MD, discusses the background for investigating the protein arginine methyltransferase 5 brain-penetrant inhibitor PRT811 in a phase 1 study in patients with recurrent high-grade glioma or uveal melanoma, as well as the agent’s mechanism of action.

Dr Halpern on Addressing Unmet Needs in Myelofibrosis

August 29th 2023

Anna B. Halpern, MD, discusses ongoing efforts to address unmet needs in patients with primary myelofibrosis.

Dr Platzbecker on the FDA Approval of Luspatercept in Lower-Risk MDS

August 29th 2023

Uwe Platzbecker, MD, discusses the significance of the FDA approval of luspatercept for patients with lower-risk myelodysplastic syndrome with anemia.

Dr McKenzie on Updates to ASCO Treatment Guidelines in Metastatic Breast Cancer

August 28th 2023

Andrew McKenzie, PhD, discusses the updates to the ASCO clinical practice guidelines for biomarker testing in patients with metastatic breast cancer.

Dr Agarwal on the Benefit of PARP Inhibitors vs Chemotherapy in mCRPC

August 28th 2023

Neeraj Agarwal, MD, discusses the benefit of PARP inhibitors compared with chemotherapy in patients with metastatic castration-resistant prostate cancer.

Dr Barata on Staying Up to Date With Evolving Treatment Approaches in Kidney Cancer

August 28th 2023

Pedro Barata, MD, MSc, discusses the importance of staying up to date with evolving treatment approaches in kidney cancer.

Dr Islam on Novel Explorations of BTK Inhibitors in MCL and CLL

August 28th 2023

Prioty Islam, MD, MSc, discusses the exploration of novel roles for BTK inhibitors in the treatment of patients with mantle cell lymphoma and chronic lymphocytic leukemia.

Dr Halpern on the Investigation of Upfront Ruxolitinib and Navitoclax in Myelofibrosis

August 28th 2023

Anna B. Halpern, MD, discusses investigational efforts to utilize ruxolitinib and navitoclax in earlier treatment lines for patients with myelofibrosis.

Dr Williams on the Mechanism of Action of ADCs in Ovarian Cancer

August 25th 2023

Heather R. Williams, MD, discusses the mechanism of action of antibody-drug conjugates and ADC targets under investigation in patients with ovarian cancer.

Dr Mead on the Use of Zanubrutinib vs Ibrutinib in MCL

August 25th 2023

Monica D. Mead, MD, discusses the efficacy and safety differences between the second-generation BTK inhibitor zanubrutinib and the first-generation BTK inhibitor ibrutinib in patients with mantle cell lymphoma.

Dr Pothuri on the Phase 3 NRG-GY018 and RUBY Trials in Endometrial Cancer

August 25th 2023

Bhavana Pothuri, MD, discusses the phase 3 NRG-GY018 and RUBY trials in patients with endometrial cancer.

Dr Reichert on Key Research Questions in Prostate Cancer

August 25th 2023

Zachery Roger Reichert, MD, PhD, discusses key research questions to explore in early-stage prostate cancer.